These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25263503)

  • 1. High HMGB1 level is associated with poor outcome of septicemic melioidosis.
    Charoensup J; Sermswan RW; Paeyao A; Promakhejohn S; Punasee S; Chularari C; Krabkraikaew S; Lertanekawattana S; Wongratanacheewin S
    Int J Infect Dis; 2014 Nov; 28():111-6. PubMed ID: 25263503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a low-dose steroid as an adjunct in the treatment, in mice, of severe sepsis caused by Burkholderia pseudomallei.
    Panomket P; Chetchotisakd P; Sermswan RW; Pannengpetch P; Wongratanacheewin S
    Ann Trop Med Parasitol; 2009 Oct; 103(7):635-46. PubMed ID: 19825285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
    Feterl M; Govan B; Engler C; Norton R; Ketheesan N
    Int J Antimicrob Agents; 2006 Nov; 28(5):460-4. PubMed ID: 17046208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.
    LaRosa SP; Opal SM; Utterback B; Yan SC; Helterbrand J; Simpson AJ; Chaowagul W; White NJ; Fisher CJ
    Int J Infect Dis; 2006 Jan; 10(1):25-31. PubMed ID: 16290015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melioidosis presenting as sepsis syndrome: a case report.
    Redondo MC; Gómez M; Landaeta ME; Ríos H; Khalil R; Guevara RN; Palavecino S; Figuera M; Caldera J; Rivera R; Calvo A; Vitelli J; Morón M; Nuñez MJ
    Int J Infect Dis; 2011 Mar; 15(3):e217-8. PubMed ID: 21195650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Delivery of Ceftazidime for the Treatment of Melioidosis in a Murine Model.
    Ruiz SI; Bowen LE; Bailey MM; Berkland C
    Mol Pharm; 2018 Mar; 15(3):1371-1376. PubMed ID: 29363975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study.
    Gaïni S; Pedersen SS; Koldkjaer OG; Pedersen C; Møller HJ
    Crit Care; 2007; 11(2):R32. PubMed ID: 17346334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model.
    Ulett GC; Norton RE; Hirst RG
    Pathology; 1999 Aug; 31(3):264-7. PubMed ID: 10503275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Epidemiology of Septic Arthritis Caused by
    Teparrukkul P; Nilsakul J; Dunachie S; Limmathurotsakul D
    Am J Trop Med Hyg; 2017 Dec; 97(6):1695-1701. PubMed ID: 29016319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: recovery from persistent septicemic melioidosis.
    Inglis TJ; Golledge CL; Clair A; Harvey J
    Am J Trop Med Hyg; 2001 Jul; 65(1):76-82. PubMed ID: 11504412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and outcomes of bacteraemic melioidosis in a teaching hospital in a northeastern state of Malaysia: a five-year review.
    Deris ZZ; Hasan H; Siti Suraiya MN
    J Infect Dev Ctries; 2010 Aug; 4(7):430-5. PubMed ID: 20818090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of activated protein C is detrimental during severe experimental gram-negative sepsis (melioidosis).
    Kager LM; Wiersinga WJ; Roelofs JJ; de Boer OJ; Meijers JC; Isermann B; van't Veer C; Van der Poll T
    Crit Care Med; 2013 Oct; 41(10):e266-74. PubMed ID: 23887233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting clinical outcomes in the management of melioidosis in Singapore: a 16-year case series.
    Chien JM; Saffari SE; Tan AL; Tan TT
    BMC Infect Dis; 2018 Sep; 18(1):482. PubMed ID: 30257647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential antibiotic-induced endotoxin release in severe melioidosis.
    Simpson AJ; Opal SM; Angus BJ; Prins JM; Palardy JE; Parejo NA; Chaowagul W; White NJ
    J Infect Dis; 2000 Mar; 181(3):1014-9. PubMed ID: 10720525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of repurposing chloroquine as an adjunct therapy for melioidosis based on a murine model of Burkholderia pseudomallei infection.
    Ganesan N; Embi N; Hasidah MS
    Trop Biomed; 2020 Jun; 37(2):303-317. PubMed ID: 33612800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei.
    Wongratanacheewin S; Kespichayawattana W; Intachote P; Pichyangkul S; Sermswan RW; Krieg AM; Sirisinha S
    Infect Immun; 2004 Aug; 72(8):4494-502. PubMed ID: 15271908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune profiling of the progression of a BALB/c mouse aerosol infection by Burkholderia pseudomallei and the therapeutic implications of targeting HMGB1.
    Laws TR; Clark GC; D'Elia RV
    Int J Infect Dis; 2015 Nov; 40():1-8. PubMed ID: 26358857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melioidosis: advances in diagnosis and treatment.
    Cheng AC
    Curr Opin Infect Dis; 2010 Dec; 23(6):554-9. PubMed ID: 20847695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis.
    Chierakul W; Anunnatsiri S; Short JM; Maharjan B; Mootsikapun P; Simpson AJ; Limmathurotsakul D; Cheng AC; Stepniewska K; Newton PN; Chaowagul W; White NJ; Peacock SJ; Day NP; Chetchotisakd P
    Clin Infect Dis; 2005 Oct; 41(8):1105-13. PubMed ID: 16163628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis.
    Wiersinga WJ; Kager LM; Hovius JW; van der Windt GJ; de Vos AF; Meijers JC; Roelofs JJ; Dondorp A; Levi M; Day NP; Peacock SJ; van der Poll T
    J Immunol; 2010 Mar; 184(6):3079-86. PubMed ID: 20142364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.